The ASCENT Trial: afatinib & chemorad w/ or w/o surgery in stage 3 EGFR NSCLC

“PFS was promising.. the prevalence of CNS-only recurrences and rapid progression after TKI discontinuation speak to unmet needs in measuring & eradicating micromet disease.”

academic.oup.com/oncolo/advance…

With information, news, vidoes, and communities just for your type of lung cancer, you can quickly and easily find everything you need to live well in the LUNGevity Patient Gateways.

Visit gateway.lungevity.org to find your Patient Gateway. #lcsm #lungcancer

Thank you to Marina K Baine, MD, PhD and the incredible thoracic oncology group at Memorial Sloan Kettering Cancer Center for the invitation to speak as a visiting professor at the #DruckenmillerLungCenter seminar series on our The Shields Lab work with lurbinectedin in #SCLC .

#LCSM SmallCellSMASHERS IU Simon Comprehensive Cancer Center

🚨🔥OncoAlert Hot off the Press.

New #Guidelines by ASCO & @IntegrativeOnc on:

“Management of #Cancer -related #Fatigue during & after cancer treatment.”

#Fatigue is a very common & distressing symptom in #Patients with #Cancer .
We CAN HELP them.

👇🏼
brnw.ch/21wJRao

Stepping up for #lunghealth and #lungcancer this morning with the American Lung Association’s Texas Two-Step!

Honored to lead our MD Anderson Cancer Center team! #lcsm #EndCancer 🏃🏽‍♂️🫁

High-yield IASLC Academy session this morning 🔥

🔸ACCE(ing) your presentations Rami Manochakian MD, FASCO 🇺🇸🇸🇾CancerEducation
🔹Publish or Perish Christian Rolfo

Grateful to the co-chairs & faculty who are volunteering their time and expertise! #lcsm

LOVE seeing more approvals in small cell! While exciting - education on cytokine release syndrome (CRS ) recognition and management is imperative ! OncoAlert SmallCellSMASHERS

I have been Singhing this Eric guy’s praise for a while- read this and you will see why!😉

➡️ Practice changing + paradigm altering news for small cell #lungcancer !
FDA Oncology grants acc. approval to tarlatamab (DLL3 BiTE). ORR 40%, mDOR 9.7mo in pre-treated population. Watch for CRS + ICANS. Much needed advance for SCLC - wow! OncoAlert

fda.gov/drugs/resource…

CM77T NEJM by Drs. Cascone M.Provencio Perioperative (chemo-nivo followed by adjuvant nivo) vs. neoadj chemo alone. Key image below, early days but new landmark analysis shows potential benefit from the adjuvant component for pts who have definitive surgery? #lcsm IASLC

Laura Book Christine Lovly, MD, PhD Eric K. Singhi, MD Balazs Halmos ASCO OncoAlert MD Anderson Cancer Center EGFR Positive UK ASCOPost Conquer Cancer, the ASCO Foundation Jill Feldman LungCancerRx 🫁💊 Oncology Brothers This exploratory analysis is interesting : onclive.com/view/dr-j-nne-…

🚨🔥OncoAlert Hot off the press.

U.S. FDA granted #accelerated approval to #Tarlatamab -dlle (bispecific T-cell engager targeting #DLL3 and #CD3 )
for #ExtensiveStage #SmallCell #LungCancer with disease progression after platinum-based #Chemotherapy .

👇🏼
fda.gov/drugs/resource…

Christine Lovly, MD, PhD Eric K. Singhi, MD Balazs Halmos ASCO OncoAlert MD Anderson Cancer Center EGFR Resisters EGFR Positive UK ASCOPost Conquer Cancer, the ASCO Foundation Jill Feldman LungCancerRx 🫁💊 👏👏👏 phenomenal work Eric K. Singhi, MD and Balazs Halmos on this piece/practical analysis of the available data. Hopefully we will see updated data on #MARIPOSA (high risk patients) at #ASCO24 ! A poll we did to understand sequencing shortly after ESMO data last year 👇! But it will

🚨 FDA Oncology grants accelerated approval for tarlatamab (DLL3 targeting BiTE molecule) for relapsed es- small cell lung cancer after platinum-based therapy. A win for #lcsm ‼️ Amgen Oncology OncoAlert LungCancerRx 🫁💊

Eric- btw- great timing on getting our The ASCO Post ASCO Daily News piece out on the FLAURA2/MARIPOSA data today! Eric K. Singhi, MD

Rami Manochakian MD, FASCO 🇺🇸🇸🇾CancerEducation LungCancerRx 🫁💊 Eric K. Singhi, MD Oncology Brothers OncoDaily H. Jack West, MD Nathan A. Pennell MD, PhD, FASCO Dr Riyaz Shah gilberto lopes Narjust Florez, MD, FASCO Aakash Desai, MD, MPH Alfredo Addeo MD Dr. Amy C. Moore Christian Rolfo Charu Aggarwal, MD, MPH, FASCO Dr. Estela Rodriguez Sandip Patel MD Sanjay Popat Balazs Halmos Dr. Nagla Abdel Karim Lynne Eldridge MD nejm.org/doi/full/10.10…

Grateful to have another option, but this is definitely not a home run

50 % ORR

PFS around 4-5 months

Also not many pt in trial got I/O upfront & unclear how it will change responses etc

With FLAURAishing new frontline combination therapies for EGFR+ mNSCLC yet incomplete data—What to do NOW in clinic? 🆘

Balazs Halmos & I share our thoughts for #ASCODailyNews 👇🏽

dailynews.ascopubs.org/do/deciding-be…

ASCO OncoAlert #lcsm

📣🔥OncoAlert Hot Off The Press.

Just published NEJM

Results of #Checkmate 77T trial of:

#Perioperative #Nivolumab (neoadjuvant nivo + chemo followed by surgery followed by adjuvant nivo) in stage IIA-IIIB #NSCLC showing:

⬆️ #DFS & ⬆️ #PCR

👇🏼
nej.md/3VaMtbX

🔥Hot off the press in NEJM

#CM77T Perioperative Nivolumab in Resectable NSCLC

▪️EFS HR 0.58
▪️pCR 25% (v ~5% chemo alone)

Another emerging perioperative option for our patients with stage IIA-IIIB NSCLC #lcsm OncoAlert

👉🏽 nejm.org/doi/full/10.10…

📣 Join Narjust Florez, MD, FASCO and I as we discuss women & Lung cancer - topics we NEED TO TALK ABOUT MORE!
1) Body image 
2) Complimentary medicine 
3) Financial toxicity 
4) Family dynamics 
5) #FlorezLab Pregnancy and Lung CA registry
SIGN UP BELOW : 5/15 at 3PM Lung Cancer Research Foundation